Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Is TAVR too common among younger patients? New data prompt a ‘call to action’
Experts agree that most patients younger than 65 should be treated with surgery instead of TAVR. According to a new real-world analysis, however, more and more of these patients are undergoing TAVR.
First-of-its-kind drainage device helps limit heart failure rehospitalizations
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
SCAI seeks female interventional cardiologists for radiation risk study
Concerns about radiation are believed to be a major reason so few women pursue a career in interventional cardiology. Are they right to be worried? SCAI hopes its new analysis can shed some light on this topic.
FDA clears high-pressure balloon catheter for BAV procedures
The new device from Arizona-based Corvention was built to withstand the extreme pressures associated with treating severely calcified valves.
New coronary IVL tech from Boston Scientific impresses in first-in-human study
The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.

Is TAVR too common among younger patients? New data prompt a ‘call to action’

Experts agree that most patients younger than 65 should be treated with surgery instead of TAVR. According to a new real-world analysis, however, more and more of these patients are undergoing TAVR.

The WhiteSwell eLym catheter-based device for lymphatic drainage in acute decompensated heart failure (ADHF) patients.

First-of-its-kind drainage device helps limit heart failure rehospitalizations

This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.

SCAI is inviting younger female interventional cardiologists and fellows within five years of training to participate in the WONDER (Women Exposed to Occupational Doses of Radiation) study.

SCAI seeks female interventional cardiologists for radiation risk study

Concerns about radiation are believed to be a major reason so few women pursue a career in interventional cardiology. Are they right to be worried? SCAI hopes its new analysis can shed some light on this topic.

FDA clears high-pressure balloon catheter for BAV procedures

The new device from Arizona-based Corvention was built to withstand the extreme pressures associated with treating severely calcified valves.

Boston Scientific's Seismiq 4CE Coronary IVL Catheter

New coronary IVL tech from Boston Scientific impresses in first-in-human study

The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.

‘Population autopsy’ finds the US with more avoidable deaths than other wealthy countries

The United States appears to be leading all high-income countries in an unfortunate, distinctly undesirable statistical category.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Bayer's new imaging agent for cardiac amyloidosis impresses in clinical trial

The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.

Subhasis Chatterjee, MD. FACS, FACC, FCCP, Associate Professor of Surgery, Director Thoracic Surgical ICU and ECMO Program, Texas Heart Institute at CHI Baylor St. Lukes, explains the new 2026 expert consensus on heparin induced thrombocytopenia (HIT) released at the American Association for Thoracic Surgery (AATS) 2026 annual meeting. #AATS #AATS2026 #AATS26

AATS helps heart surgeons diagnose and manage heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.